Amara Okoro spends her week deciding which infections actually need a drug and which need time, and she brings that same triage to the ledger forum. She trained in internal medicine at Johns Hopkins, then infectious disease at Emory, and now leads the antimicrobial stewardship programme at a Boston teaching hospital.
On the threads her instinct is to slow people down: why an antibiotic does nothing for a virus, why a fluoroquinolone is a heavier tool than amoxicillin, and why a parasite must be named before it is treated. She cites primary sources when readers ask about resistance patterns — CDC surveillance reports, FDA safety communications, and WHO essential-medicines lists — because a forum answer should point somewhere verifiable.
Her ivermectin threads attract the most noise online, so she repeats the same triage there: approved antiparasitic uses with decades of trial data versus viral claims that large randomized studies have already settled. When someone mentions travel through central Africa, she walks through Loa loa screening before any dose. When a household has scabies, she explains why treating everyone at once beats cream alone.
For ciprofloxacin she emphasises indication and duration: effective for many urinary and abdominal infections when local resistance still permits, but a poor first choice for uncomplicated cystitis where narrower agents suffice. She warns about tendon risk, QT prolongation with other medicines, and the temptation to keep a leftover course for the next cold.
Amoxicillin is the workhorse she defends against both under-use and over-use. She explains where guidelines still place it first-line — strep throat, many ear infections, dental prophylaxis — and where stewardship programmes have moved away from it because resistance has climbed. She compares amoxicillin to co-amoxiclav without treating them as interchangeable.
Before joining the ledger she spent three years on a Médecins Sans Frontières roster in West Africa, where mass ivermectin rounds and antibiotic rationing were daily reality rather than textbook cases. That field work is why she treats formulary entries as living documents: resistance maps shift, labels update, and a thread answer from 2024 may need a footnote by 2026.
She covers ivermectin, ciprofloxacin and amoxicillin on True Health Ledger. Nothing here is a prescription — it is the unhurried version of the conversation she has in clinic, written so a reader can bring better questions to their own prescriber.
Outside the ledger she publishes stewardship bulletins for her hospital pharmacy team and guest-lectures on antiparasitic mass-treatment programmes. Those slides feed back into the formulary when resistance maps or donation-programme data shift.
Readers who disagree with a thread answer are encouraged to bring the exchange to their own clinician — the ledger is a teaching aid, not a chart note.